Dapagliflozin (a sodium glucose co-transporter 2 [SGLT2] inhibitor), when indicated concomitantly with standard therapy, reduces significantly the risk of worsening heart failure events and cardiovascular events, and improves symptoms in patients with heart failure and reduced ejection fraction according to this new work presented during last Sunday’s scientific sessions at the European Society of Cardiology...
For patients with ST-segment elevation acute myocardial infarction and multivessel disease beyond the culprit artery, complete revascularization is superior to culprit-only treatment as regards the final endpoint, a composite of cardiovascular death, infarction, and ischemia-driven revascularization over a mean follow-up of 3 years. This information derives from long-awaited randomized study COMPLETE, finally presented at the...
Learn about the presentations exhibited during the 10th ProEducar Fellows Course, held in 2019 in the city of Sao Paulo. The course was a real success, as it was attended by more than 150 professionals and renowned international interventionists, such as Doctors Stone, Grines, Granada, Hijazi, Abizaid, Mendiz, Lemos and Leiva Pons. We thank all...
For over ten years, SOLACI’s Regional Sessions have set trends in Latin America, promoting medical education, advancing scientific development and research, fostering interventionism’s best practices and organizing scientific events of utmost importance for our specialty in different countries across Latin America and the Caribbean. This is why both SOLACI and SBHCI regard the presence of...
1- What Antiplatelet Therapy Should We Use in Patients with Stroke/TIA? Interesting Results for the POINT Trial The New England Journal of Medicine (NEJM) recently published an article about the POINT trial (simultaneously presented at the European Stroke Organisation Conference), a long-awaited randomized clinical trial to assess the efficacy and safety of dual antiplatelet therapy...
1- New High Blood Pressure Guidelines The wait is finally over: the high blood pressure guidelines that have been in the works for the past 3 years saw the light of day at the American Heart Association (AHA) 2017 Scientific Sessions. Read more 2- New European Hypertension Guidelines Contrast with American Recommendations The European...
1- The CULPRIT-SHOCK Study Is Finally Published in NEJM and It Is Bound to Change Guidelines During SOLACI’s coverage of the TCT 2017 Congress in Denver, Colorado, we already mentioned some of the outcomes of this study that has arrived to revolutionize clinical practice, given the differences between its results and those of the classic...
We are deeply thankful to all interventional physicians who, motivated by their great scientific and educational vocation, presented their works at the “José Gabay” Course. Read the presentations below: Module I: Fundamentals and Basic Elements. Leiva Pons, José Luis. “Vascular Closure Devices. Step by Step.” (Spanish version) García García, Hector. “Current Status of Coronary Intervention:...
Transradial access should be the access of choice in patients with acute coronary syndrome, while bivalirudin has not shown any benefit for this population. The long-term follow-up from the MATRIX (Minimizing Adverse Hemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox) trial confirms the results at 30 days: transradial access is here to stay...
Once again, the most relevant scientific societies in the world have trusted SOLACI Congress to debate different topics on interventional cardiology, and so we have put together different joint sessions tailored to your interests, to be presented by the most prestigious faculty members in the world. Next, see what joint sessions you will be able...